P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease

Despite levodopa’s superior efficacy in reducing the motor symptoms of Parkinson’s disease (PD), its risk to induce motor complications requires consideration of the pros and cons of initiating treatment with levodopa-sparing strategies. The current drive toward early levodopa monotherapy is primari...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Giladi, Nir, Poewe, Werner, Brotchie, Jonathan, Friedman, Hadas, Oren, Sheila, Litman, Pninit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056484/
https://www.ncbi.nlm.nih.gov/pubmed/35267155
http://dx.doi.org/10.1007/s12325-022-02097-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056484/
https://www.ncbi.nlm.nih.gov/pubmed/35267155
http://dx.doi.org/10.1007/s12325-022-02097-2

Ejemplares similares